Publicaciones en colaboración con investigadores/as de Hospital de Cabueñes (11)

2023

  1. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539

2022

  1. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2021

  1. Btla/hvem axis induces nk cell immunosuppression and poor outcome in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 8

  2. Lag‐3 blockade with relatlimab (Bms‐986016) restores anti‐leukemic responses in chronic lymphocytic leukemia

    Cancers, Vol. 13, Núm. 9

2019

  1. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling

    Frontiers in Immunology, Vol. 10

2018

  1. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia

    Frontiers in immunology, Vol. 9, pp. 2917

2015

  1. On the prediction of Hodgkin lymphoma treatment response

    Clinical and Translational Oncology, Vol. 17, Núm. 8, pp. 612-619

2014

  1. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease

    PLoS ONE, Vol. 9, Núm. 10

2013

  1. Lenalidomide and chronic lymphocytic leukemia

    BioMed Research International, Vol. 2013

2012

  1. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: Association with soluble MICA shedding

    Cancer Immunology, Immunotherapy, Vol. 61, Núm. 8, pp. 1201-1210

2009

  1. Estudio epidemiológico y comparación de los índices pronósticos del MD Anderson Cancer Center y el índice del Gruppo Italiano Malattie Ematologiche Maligne dell′ Adulto en pacientes con leucemia linfática crónica de células B

    Medicina Clinica, Vol. 133, Núm. 5, pp. 161-166